Your browser doesn't support javascript.
loading
Kinin B2 Receptor Activation Prevents the Evolution of Alzheimer's Disease Pathological Characteristics in a Transgenic Mouse Model.
Nunes, Marielza Andrade; Toricelli, Mariana; Schöwe, Natalia Mendes; Malerba, Helena Nascimento; Dong-Creste, Karis Ester; Farah, Daniela Moura Azevedo Tuma; De Angelis, Katia; Irigoyen, Maria Claudia; Gobeil, Fernand; Araujo Viel, Tânia; Buck, Hudson Sousa.
Afiliação
  • Nunes MA; Department of Physiological Sciences, Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo 01221-020, Brazil.
  • Toricelli M; Department of Physiological Sciences, Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo 01221-020, Brazil.
  • Schöwe NM; School of Arts, Sciences and Humanities, University of Sao Paulo, Sao Paulo 03828-080, Brazil.
  • Malerba HN; School of Arts, Sciences and Humanities, University of Sao Paulo, Sao Paulo 03828-080, Brazil.
  • Dong-Creste KE; Department of Physiological Sciences, Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo 01221-020, Brazil.
  • Farah DMAT; Heart Institute (Incor), Hypertension Unit, University of Sao Paulo, Sao Paulo 05403-900, Brazil.
  • De Angelis K; Department of Physiology, Federal University of São Paulo (UNIFESP), Sao Paulo 04023-901, Brazil.
  • Irigoyen MC; Department of Physiology, Federal University of São Paulo (UNIFESP), Sao Paulo 04023-901, Brazil.
  • Gobeil F; Translational Physiology Laboratory, Universidade Nove de Julho (UNINOVE), Sao Paulo 01504-001, Brazil.
  • Araujo Viel T; Heart Institute (Incor), Hypertension Unit, University of Sao Paulo, Sao Paulo 05403-900, Brazil.
  • Buck HS; Department of Pharmacology and Physiology, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Pharmaceuticals (Basel) ; 13(10)2020 Oct 01.
Article em En | MEDLINE | ID: mdl-33019732
BACKGROUND: Alzheimer's disease is mainly characterized by remarkable neurodegeneration in brain areas related to memory formation. This progressive neurodegeneration causes cognitive impairment, changes in behavior, functional disability, and even death. Our group has demonstrated changes in the kallikrein-kinin system (KKS) in Alzheimer's disease (AD) experimental models, but there is a lack of evidence about the role of the KKS in Alzheimer's disease. AIM: In order to answer this question, we evaluated the potential of the kinin B2 receptors (BKB2R) to modify AD characteristics, particularly memory impairment, neurodegeneration, and Aß peptide deposition. METHODS: To assess the effects of B2, we used transgenic Alzheimer's disease mice treated with B2 receptor (B2R) agonists and antagonists, and performed behavioral and biochemical tests. In addition, we performed organotypic hippocampal culture of wild-type (WT) and transgenic (TG) animals, where the density of cytokines, neurotrophin BDNF, activated astrocyte marker S100B, and cell death were analyzed after treatments. RESULTS: Treatment with the B2R agonist preserved the spatial memory of transgenic mice and decreased amyloid plaque deposition. In organotypic hippocampal culture, treatment with B2R agonist decreased cell death, neuroinflammation, and S100B levels, and increased BDNF release. CONCLUSIONS: Our results indicate that the kallikrein-kinin system plays a beneficial role in Alzheimer's disease through B2R activation. The use of B2R agonists could, therefore, be a possible therapeutic option for patients diagnosed with Alzheimer's disease.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça